How to Stop Hot Flashes: Evidence-Based Strategies
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 16 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
How to stop hot flashes, evidence-based: HRT, fezolinetant, SSRIs/SNRIs, gabapentin, CBT, and lifestyle — what works, for whom, and how to decide.
The WHI unnecessarily frightened women and left them suffering with very real symptoms, possibly preventing them from taking a life-changing, even life-prolonging treatment. HRT can have beneficial impacts on bones, brains, and heart — and many common fears around hormone therapy are not supported by the latest scientific evidence.
If you’re trying to figure out how to stop hot flashes — or at least how to make them livable — you have more evidence-based options than you’ve probably been told. The treatment menu now includes prescription hormone therapy, a relatively new non-hormonal medication, several long-established non-hormonal prescriptions, a structured behavioral therapy with strong trial data, and a small set of lifestyle interventions that actually work.
This guide walks through each option, what the evidence says about effect size, and how to think about which one fits your situation. The most important thing isn’t which treatment is “best” in the abstract — it’s which one matches your symptom severity, medical history, and preferences in a real conversation with a clinician.
Key takeaways
Hormone therapy remains the most effective treatment for moderate-to-severe vasomotor symptoms in appropriately selected women, per the Menopause Society 2022 position statement.
Fezolinetant (Veozah), approved in 2023, is a non-hormonal prescription with substantial effect sizes from the SKYLIGHT trials.
SSRIs and SNRIs at low doses — particularly paroxetine, escitalopram, and venlafaxine — have well-established efficacy for vasomotor symptoms.
Gabapentin works, especially for night-time symptoms, but side effects limit some women.
Cognitive Behavioral Therapy for Menopausal Symptoms (CBT) has RCT-grade evidence for reducing the impact and bother of hot flushes.
Lifestyle interventions help at the margins but rarely solve moderate-to-severe symptoms on their own.
The short answer: what actually stops hot flashes
The single most effective treatment for moderate-to-severe vasomotor symptoms is hormone therapy, with effect sizes typically in the 70-90% reduction range. The most effective non-hormonal prescription is currently fezolinetant. SSRIs, SNRIs, and gabapentin provide meaningful relief — typically a 40-65% reduction depending on agent and dose. CBT meaningfully reduces the impact and bother of hot flushes even when frequency changes are modest. Lifestyle changes help at the margins.
Which option fits depends on whether your symptoms are mild, moderate, or severe; your medical history (particularly breast cancer, cardiovascular history, and venous thromboembolism risk); your preferences; and your tolerance for side effects.
The framing the Menopause Society’s 2022 Hormone Therapy Position Statement and NICE Guideline NG23 (updated November 2024) both support is shared decision-making: hormone therapy for women who can use it and want it, non-hormonal prescription options for women who can’t or don’t, behavioral interventions for everyone, lifestyle as a foundation.
Hormone therapy: still the most effective option
Systemic hormone therapy — estrogen alone if you’ve had a hysterectomy, estrogen plus a progestogen if you still have a uterus — is the most effective treatment for moderate-to-severe vasomotor symptoms. Effect sizes from randomized trials typically show 70-90% reduction in hot flush frequency and substantial reductions in severity.
The current consensus framework, supported by the Menopause Society 2022 statement and NICE NG23, is straightforward:
For women under 60 or within 10 years of their final menstrual period with moderate-to-severe vasomotor symptoms, the benefits of hormone therapy generally outweigh the risks.
Outside that window, the balance shifts and individual evaluation matters more.
Specific contraindications include current or recent breast cancer, active liver disease, history of estrogen-sensitive cancer, unexplained vaginal bleeding, recent stroke or coronary heart disease, and current or recent venous thromboembolism (though transdermal preparations may carry lower VTE risk than oral).
Forms matter:
HRT is a treatment that is safe, very similar to your body's hormones, and doctor-recommended. There shouldn't be so much stigma around hormone therapy because the benefits outweigh the risks.
Oral estrogen (estradiol, conjugated estrogens)
Transdermal estrogen (patches, gels, sprays) — preferred in many women because of lower VTE risk
Combined preparations for women with a uterus include either oral micronized progesterone or a synthetic progestin
The risk picture from the WHI has been substantially reframed since the original 2002 publication. The Manson 2017 JAMA 18-year follow-up of the WHI cohort, alongside the KEEPS trial and the ELITE trial, supports the “timing hypothesis” — benefit-risk is most favorable when therapy is started in early postmenopause rather than years out.
This is a conversation worth having with a clinician who’s current with the evidence. Many clinicians trained before the post-WHI re-evaluation still operate from a more restrictive framework than current guidelines support.
Fezolinetant (Veozah): the newer non-hormonal option
Fezolinetant, brand name Veozah, was FDA-approved in 2023 as the first medication in a new class — a neurokinin-3 (NK3) receptor antagonist. It works directly on the brain neurons in the hypothalamus that drive vasomotor symptoms, without affecting estrogen levels.
The pivotal Phase 3 trials — SKYLIGHT 1 and 2, and SKYLIGHT 4 — demonstrated significant reductions in both frequency and severity of moderate-to-severe vasomotor symptoms compared with placebo. Effect sizes in the active treatment arms typically showed reductions of 60% or more in hot flush frequency from baseline at 12 weeks.
Practical notes:
It’s a daily oral medication, dosed at 45 mg once daily.
It’s non-hormonal, making it an option for women who can’t or don’t want hormone therapy — including breast cancer survivors and women with VTE history.
Common side effects include headache, abdominal pain, diarrhea, and elevated liver enzymes.
Liver function monitoring is required at baseline and periodically, per the FDA label, after post-marketing reports of hepatic injury.
Onset of effect is gradual over weeks.
Fezolinetant has a different conversation profile than hormone therapy because the risk and benefit picture is narrower (it specifically targets vasomotor symptoms and doesn’t have the broader effects — positive or negative — of systemic estrogen). For a deeper dive, our Veozah guide covers the medication in detail.
SSRIs and SNRIs: established non-hormonal prescriptions
There's a lot of chatter around hormone replacement therapy. A lot of fear mongering, a lot of 'only I can do this for you the right way.' What I tell all my patients is that HRT is the replacing of the endocrine factors — the estrogen and progesterone — that have gone missing from a woman's body.
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have an established evidence base for vasomotor symptoms at doses generally lower than those used for depression. The most-studied agents:
Paroxetine — the only SSRI with FDA approval specifically for vasomotor symptoms (low-dose, 7.5 mg). Older trials documented meaningful reductions in hot flush frequency and severity.
Escitalopram — the MsFLASH escitalopram trial published by Joffe and colleagues in 2014 (Menopause) demonstrated significant reductions in hot flush frequency and bother at 10-20 mg daily.
Venlafaxine (SNRI) — multiple trials demonstrate efficacy, with some head-to-head data suggesting comparable benefit to low-dose estrogen for vasomotor symptoms specifically.
Desvenlafaxine (SNRI) — also supported by trial data.
Practical notes:
These doses are lower than typical depression-treatment doses but still carry SSRI/SNRI side effects: GI upset, sexual side effects, sleep changes, withdrawal symptoms if stopped abruptly.
Paroxetine specifically interacts with tamoxifen (it inhibits the CYP2D6 enzyme that activates tamoxifen). It should not be used by women on tamoxifen — venlafaxine, escitalopram, or citalopram are preferred in that population. The tamoxifen side effects guide covers this drug interaction in more depth.
They’re a primary option for women with breast cancer history, contraindications to hormone therapy, or preference for non-hormonal management.
The Menopause Society’s 2023 Nonhormone Therapy Position Statement endorses SSRIs and SNRIs as evidence-based options for vasomotor symptoms.
Gabapentin: especially useful for night-time symptoms
Gabapentin, originally an anticonvulsant, has well-documented efficacy for vasomotor symptoms — particularly nocturnal symptoms that disrupt sleep. Typical dosing for menopause-related symptoms ranges from 300 mg at bedtime up to 900 mg per day in divided doses.
Practical notes:
It’s a reasonable option when night sweats are the dominant problem and sleep disruption is the biggest cost.
Side effects include drowsiness (which can be a feature for night dosing), dizziness, and weight gain.
It’s not first-line for daytime-dominant hot flushes for most women, but it’s a real option, particularly when other options aren’t appropriate.
The 2023 Nonhormone Therapy Position Statement also endorses gabapentin as an evidence-based option.
Oxybutynin is another non-hormonal option with growing evidence for vasomotor symptoms, particularly for women with overlapping urinary symptoms. Clonidine has older evidence but is less commonly used now due to side effect profile.
CBT for menopausal symptoms
Cognitive Behavioral Therapy specifically adapted for menopausal symptoms has rigorous trial evidence — particularly the MENOS 1 (Mann 2012, Lancet Oncology) and MENOS 2 (Ayers 2012, Menopause) trials, which demonstrated significant reductions in the impact and bother of hot flushes through structured CBT delivered in groups or individually.
The key distinction with CBT for menopause: it doesn’t always reduce the frequency of hot flushes — it reduces the impact. Women report symptoms feel less disruptive, less anxiety-provoking, and easier to navigate. For many women, that’s the outcome that actually matters.
Practical notes:
A typical course is 4-8 sessions covering psychoeducation, stress and trigger management, cognitive restructuring of catastrophizing thoughts during a flush, and behavioral strategies.
It works alongside hormone therapy or non-hormonal prescriptions — not in opposition to them.
It’s particularly useful for women whose vasomotor symptoms come with significant anxiety, sleep disruption, or workplace impact.
Availability is variable but increasing, including through digital platforms.
CBT is supported as an evidence-based option by the Menopause Society 2023 Nonhormone Therapy Position Statement.
Lifestyle interventions that actually work
The lifestyle category has the most marketing noise and the weakest individual effect sizes — but a few interventions are supported by enough evidence to be worth doing for most women.
Alcohol reduction
The single highest-yield lifestyle change. Alcohol reliably triggers and intensifies hot flushes for the majority of women who drink. Even one drink with dinner often worsens night sweats and fragments sleep. A two-week trial of abstinence reveals how much of your symptom picture is alcohol-related.
Avoiding identifiable triggers
Common triggers include hot drinks, spicy food, warm environments, tight clothing, and acute stress. Trigger patterns vary individually; tracking for two weeks helps identify yours.
Cooling strategies
Multiple thin layers rather than one heavy outfit. Lowering the bedroom thermostat to 65-68°F. Moisture-wicking sleepwear (merino or technical fabrics, not cotton). Personal cooling devices have modest evidence and are reasonable adjuncts.
Maintaining a healthy weight
Higher BMI is consistently associated with more frequent vasomotor symptoms. Weight loss has modest but real effects on hot flush frequency in observational and intervention studies. The menopause diet guide covers the eating pattern most associated with both symptom reduction and broader health.
Exercise
Regular physical activity supports sleep, mood, body composition, and cardiovascular health — all of which interact with vasomotor symptoms. Direct effects on hot flush frequency are modest, but the indirect effects are substantial.
Mind-body practices
Paced breathing, mindfulness, yoga, and meditation have small effect sizes on hot flush severity in some trials and may help with the anxiety and sleep disruption that often accompany the symptoms.
What doesn’t reliably work
A few things deserve specific naming because they’re heavily marketed:
Most over-the-counter “hot flush supplements” — black cohosh, evening primrose oil, red clover — have mixed or negative trial data and aren’t endorsed by the Menopause Society 2023 Nonhormone Position Statement.
Bioidentical compounded hormones marketed as safer than FDA-approved hormone therapy are not safer; they’re less regulated, often inadequately tested, and not endorsed by major societies.
“Vaginal rejuvenation” energy devices marketed for hot flushes have no compelling evidence for vasomotor symptoms (and limited evidence even for genitourinary symptoms).
Most “cooling” wearables are reasonable adjuncts but don’t address the underlying problem.
The natural remedies for menopause guide walks through the broader landscape of non-prescription options with honest assessment of evidence.
How to think about which treatment fits
The conversation with a clinician should sort:
Symptom severity. Mild symptoms may respond adequately to lifestyle plus targeted lifestyle changes. Moderate-to-severe symptoms typically need pharmacologic treatment to improve substantially.
Hormone therapy eligibility. Age, time since menopause, medical history, and personal preferences all factor into whether HRT is appropriate.
Cancer history. Women with current or recent breast cancer typically can’t use systemic hormone therapy; non-hormonal options (fezolinetant, certain SSRIs/SNRIs, gabapentin, CBT) are the framework.
Cardiovascular and VTE history. These shift both whether and how to use hormone therapy, and may push toward transdermal rather than oral preparations.
Side effect tolerance. SSRIs/SNRIs have sexual side effects. Gabapentin causes sedation. Fezolinetant requires liver monitoring. Hormone therapy may cause breast tenderness and breakthrough bleeding initially.
Sleep-dominant vs. day-dominant symptoms. Night-sweats-dominant pictures might lead toward gabapentin or bedtime dosing of other agents.
For a structured way to prepare for this conversation, the talking to your doctor about menopause guide walks through what to bring and what to ask.
When to talk to a clinician
If hot flushes are affecting your sleep, work, mood, or relationships, that’s reason enough. Other triggers:
New-onset vasomotor symptoms in your 30s or early 40s (possible perimenopause, possible other causes)
Symptoms persisting more than a year that are still bothersome
Symptoms in the setting of breast cancer survivorship or anti-estrogen therapy
Current use of supplements or over-the-counter remedies that aren’t working
Symptoms accompanied by significant mood, sleep, or anxiety changes
Anything about the symptom pattern that doesn’t fit standard vasomotor symptoms (atypical timing, focal sweating, weight loss, fevers — these may warrant evaluation for other causes)
The conversation that gets you to effective treatment has three parts: (1) clearly characterized symptoms (frequency, severity, impact), (2) a complete medical history including cancer, cardiovascular, and VTE risk, (3) a clinician who’s current with both the Menopause Society and NICE evidence base. If that conversation isn’t producing a real treatment plan, finding a different clinician is appropriate.
Frequently asked questions
What’s the most effective way to stop hot flashes?
Hormone therapy, for women who can use it, has the largest effect size (70-90% reduction in frequency for moderate-to-severe symptoms). For women who can’t use HRT, fezolinetant has substantial effect sizes from the SKYLIGHT trials. SSRIs/SNRIs and gabapentin provide meaningful relief with smaller effect sizes.
Can you stop hot flashes naturally?
Some lifestyle interventions help — particularly alcohol reduction, trigger avoidance, and weight management. Effect sizes are modest. Most over-the-counter supplements marketed for hot flushes have weak or mixed evidence and aren’t endorsed by major societies.
How long does it take for treatment to work?
Hormone therapy typically produces noticeable improvement within 2-4 weeks. Fezolinetant builds effect over 4-12 weeks. SSRIs/SNRIs typically show benefit within 4-8 weeks. CBT delivers measurable improvement in symptom impact within 6-8 sessions.
Are there hot flash treatments for breast cancer survivors?
Yes. Fezolinetant is a non-hormonal option appropriate for many breast cancer survivors. Venlafaxine, escitalopram, and citalopram are SSRIs/SNRIs without significant tamoxifen interaction (paroxetine should be avoided with tamoxifen). Gabapentin and CBT are also options. The plan should be coordinated with the oncology team.
Will hot flashes go away on their own?
For most women, yes — but it can take years. SWAN data show a median vasomotor symptom duration of 7.4 years, with about 4.5 years continuing after the final menstrual period. A meaningful minority experience symptoms into their 70s. Waiting it out is reasonable for mild symptoms; effective treatment is reasonable for symptoms that are interfering with life.
Can I combine treatments?
Often yes — particularly behavioral and lifestyle interventions alongside prescription treatment. Combining multiple prescription medications for vasomotor symptoms is less common and should be discussed with a clinician.
Sources
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
The Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of Internal Medicine. 2014;161(4):249-260. (KEEPS Trial.)
Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. 2016;374(13):1221-1231. (ELITE Trial.)
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1). Lancet. 2023;401(10382):1091-1102.
Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Internal Medicine. 2014;174(7):1058-1066. (MsFLASH.)
Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1). Lancet Oncology. 2012;13(3):309-318.
Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2). Menopause. 2012;19(7):749-759.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Prescription medications referenced in this article (hormone therapy, fezolinetant, SSRIs, SNRIs, gabapentin) require evaluation by a clinician and are not appropriate for everyone. Fezolinetant requires baseline and periodic liver function monitoring per the FDA label. Paroxetine should not be used by women on tamoxifen due to CYP2D6-mediated drug interaction. Women with current or recent breast cancer, active liver disease, recent stroke, recent coronary heart disease, or current venous thromboembolism should not use systemic hormone therapy without specific specialist evaluation.
